- Home
- DTSS vs MRKR Comparison
DTSS vs MRKR Comparison
Compare DTSS & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSS
- MRKR
- Stock Information
- Founded
- DTSS 2014
- MRKR N/A
- Country
- DTSS China
- MRKR United States
- Employees
- DTSS N/A
- MRKR N/A
- Industry
- DTSS Computer Software: Prepackaged Software
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- DTSS Technology
- MRKR Health Care
- Exchange
- DTSS Nasdaq
- MRKR Nasdaq
- Market Cap
- DTSS 16.5M
- MRKR 19.1M
- IPO Year
- DTSS N/A
- MRKR N/A
- Fundamental
- Price
- DTSS $2.00
- MRKR $1.50
- Analyst Decision
- DTSS
- MRKR Strong Buy
- Analyst Count
- DTSS 0
- MRKR 3
- Target Price
- DTSS N/A
- MRKR $13.17
- AVG Volume (30 Days)
- DTSS 82.5K
- MRKR 232.7K
- Earning Date
- DTSS 05-14-2025
- MRKR 08-13-2025
- Dividend Yield
- DTSS N/A
- MRKR N/A
- EPS Growth
- DTSS N/A
- MRKR N/A
- EPS
- DTSS N/A
- MRKR N/A
- Revenue
- DTSS $56,255,129.00
- MRKR $5,696,123.00
- Revenue This Year
- DTSS N/A
- MRKR N/A
- Revenue Next Year
- DTSS N/A
- MRKR $11.28
- P/E Ratio
- DTSS N/A
- MRKR N/A
- Revenue Growth
- DTSS 144.20
- MRKR 71.53
- 52 Week Low
- DTSS $1.63
- MRKR $0.95
- 52 Week High
- DTSS $7.67
- MRKR $5.99
- Technical
- Relative Strength Index (RSI)
- DTSS 40.28
- MRKR 50.81
- Support Level
- DTSS $1.91
- MRKR $1.41
- Resistance Level
- DTSS $2.18
- MRKR $1.53
- Average True Range (ATR)
- DTSS 0.14
- MRKR 0.16
- MACD
- DTSS -0.03
- MRKR -0.03
- Stochastic Oscillator
- DTSS 15.09
- MRKR 9.43
About DTSS Datasea Inc.
Datasea Inc is a technology company. Its offers provides acoustic business services (focusing on high-tech acoustic technologies and applications such as ultrasound, infrasound, and Schumann resonance), 5G application services (5G AI multimodal digital business), and other products and services to various corporate and individual customers. The business activity of the group functions through China.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.